CJC-1295 (no DAC)

A short-acting GHRH analog — the no-DAC form of CJC-1295 — used for pulsatile growth-hormone release that stays close to natural physiology.

01Overview

CJC-1295 without DAC, also known as Modified GRF 1-29 (Mod GRF 1-29), is a synthetic analog of the first 29 amino acids of growth-hormone-releasing hormone (GHRH) — the same active region as sermorelin, with stabilizing modifications for improved durability.

It is the counterpart to CJC-1295 with DAC: where the DAC (Drug Affinity Complex) version binds albumin to stretch its half-life to roughly 6–8 days, the no-DAC form clears quickly, which is exactly why it is favored for pulsatile GH research.

02Mechanism

• Binds GHRH receptors on pituitary somatotrophs, triggering cAMP/PKA-mediated growth-hormone synthesis and release.
• Its short half-life (~30 minutes to 2 hours) drives pulsatile GH release rather than a sustained elevation.
• By preserving natural pulsatility, it carries a lower risk of receptor desensitization than long-acting alternatives.

03Research uses

• Growth-hormone-axis and pulsatility research
• GHRH-receptor signaling models
• Combination studies with GHRPs such as Ipamorelin

04Key findings

• Peak GH levels are reported around 15–30 minutes after subcutaneous administration, reflecting rapid absorption.
• Studies indicate it can raise basal GH while preserving the natural pulsatile rhythm.
• It is mechanistically complementary to ghrelin-receptor secretagogues — the basis for the CJC-1295 + Ipamorelin pairing.

05Handling & reconstitution

• Supplied lyophilized; allow the vial to reach room temperature before reconstitution.
• Reconstitute with bacteriostatic water using sterile technique; swirl gently.
• Store reconstituted solution refrigerated and away from light — do not freeze; discard if it becomes cloudy or discolored.